drugset / Trial / NCT04381689

Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactived Split Influenza Vaccine in Healthy Infants

NCT04381689

Phase 3 Completed 260 enrolled Il-Yang Pharm. Co., Ltd.
RandomizedParallel-groupDouble-blindPrevention

Summary

The purpose of this study is to evaluate the safety and immunogenicity of IL-YANG Inactivated Split Influenza Vaccine (IL-YANG Quadrivalent Seasonal Influenza Vaccine) in healthy infants from 6 months to under 3 years of age(≥ 6 months and \< 3 years)

Timeline

Start
2024-10-23
Primary completion
2025-05-20
Completion
2025-10-22

Drugs

EvaluationDrugModalityDoseRoute
Comparator Fluarix Tetra Vaccine 0.5 ml
Subject IL-YANG Quadrivalent Seasonal Influenza Vaccine Vaccine 0.5 ml

Indications

No indication recorded.